JP2022514264A5 - - Google Patents

Info

Publication number
JP2022514264A5
JP2022514264A5 JP2021534645A JP2021534645A JP2022514264A5 JP 2022514264 A5 JP2022514264 A5 JP 2022514264A5 JP 2021534645 A JP2021534645 A JP 2021534645A JP 2021534645 A JP2021534645 A JP 2021534645A JP 2022514264 A5 JP2022514264 A5 JP 2022514264A5
Authority
JP
Japan
Prior art keywords
disorder
pharmaceutical composition
composition according
anxiety
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021534645A
Other languages
English (en)
Japanese (ja)
Other versions
JP7487204B2 (ja
JP2022514264A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066894 external-priority patent/WO2020131899A1/en
Publication of JP2022514264A publication Critical patent/JP2022514264A/ja
Publication of JP2022514264A5 publication Critical patent/JP2022514264A5/ja
Application granted granted Critical
Publication of JP7487204B2 publication Critical patent/JP7487204B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534645A 2018-12-17 2019-12-17 有機化合物 Active JP7487204B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780804P 2018-12-17 2018-12-17
US62/780,804 2018-12-17
PCT/US2019/066894 WO2020131899A1 (en) 2018-12-17 2019-12-17 Organic compound

Publications (3)

Publication Number Publication Date
JP2022514264A JP2022514264A (ja) 2022-02-10
JP2022514264A5 true JP2022514264A5 (cg-RX-API-DMAC7.html) 2022-12-23
JP7487204B2 JP7487204B2 (ja) 2024-05-20

Family

ID=71102816

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534645A Active JP7487204B2 (ja) 2018-12-17 2019-12-17 有機化合物

Country Status (11)

Country Link
US (2) US12195462B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898221A4 (cg-RX-API-DMAC7.html)
JP (1) JP7487204B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210104785A (cg-RX-API-DMAC7.html)
CN (1) CN113423568A (cg-RX-API-DMAC7.html)
AU (1) AU2019403150B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011792A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121635A1 (cg-RX-API-DMAC7.html)
IL (1) IL283961A (cg-RX-API-DMAC7.html)
MX (1) MX2021007217A (cg-RX-API-DMAC7.html)
WO (1) WO2020131899A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
ES3047409T3 (en) 2018-12-17 2025-12-03 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
US12331052B2 (en) 2018-12-21 2025-06-17 Intra-Cellular Therapies, Inc. Organic compounds
JP7377871B2 (ja) 2018-12-21 2023-11-10 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN121152625A (zh) * 2023-02-17 2025-12-16 细胞内治疗公司 用于调节神经系统的卢美哌隆和其衍生物
CN120192319B (zh) * 2023-12-22 2026-02-06 江苏恩华药业股份有限公司 一种卢美哌隆中间体化合物的制备方法
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
ATE59289T1 (de) 1985-10-09 1991-01-15 Desitin Arzneimittel Gmbh Verfahren zur herstellung einer darreichungsund dosierungsform fuer arzneimittel-wirkstoffe, reagentien oder andere wirkstoffe.
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
DE69915346T2 (de) 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
WO2000077001A1 (en) 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
CN101983058A (zh) 2008-02-05 2011-03-02 克莱拉有限公司 缓解抑郁症或改善认知的组合物和方法
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CA2725342C (en) 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物
DE102010041942B4 (de) 2010-10-04 2013-01-17 Lear Corporation Bewegliche Kopfstützen für Fahrzeugsitze
AU2012295810B2 (en) 2011-08-16 2016-05-26 Tosho, Inc. Tablet splitting apparatus
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
BR112015005743A2 (pt) 2012-09-14 2017-07-04 Abbvie Deutschland derivados tricíclicos de quinoxalina e quinolina
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CA2922488C (en) 2013-09-11 2022-04-26 Audio-Technica U.S., Inc. Maintaining clock synchronization in a digital network without continuous transmission
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
WO2017117514A1 (en) 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
US20200392135A1 (en) 2016-03-25 2020-12-17 Intra-Cellular Therapies, Inc. Organic compounds
IL281050B2 (en) * 2016-03-25 2023-04-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
WO2017172811A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
WO2017172784A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
HUE057055T2 (hu) 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
DK3596069T3 (da) 2017-03-17 2022-08-01 Scripps Research Inst Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
US20220160704A2 (en) 2018-08-08 2022-05-26 Torralva Medical Therapeutics Llc Compositions for opiate and opioid prevention and reversal, and methods of their use
US12331052B2 (en) 2018-12-21 2025-06-17 Intra-Cellular Therapies, Inc. Organic compounds
JP7377871B2 (ja) 2018-12-21 2023-11-10 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
US10668097B1 (en) 2019-03-21 2020-06-02 Direct Digital, LLC Testosterone enhancing compositions and methods
IL286938B1 (en) 2019-04-04 2026-05-01 Intra Cellular Therapies Inc Methods for treating neuropathic pain
WO2020223894A1 (en) 2019-05-07 2020-11-12 Nirsum Laboratories, Inc. Opioid receptor antagonist prodrugs

Similar Documents

Publication Publication Date Title
CN1832734B (zh) 用于治疗抑郁症的取代的2-氨基1,2,3,4-四氢化萘
JP2022515766A5 (cg-RX-API-DMAC7.html)
JP2005539068A5 (cg-RX-API-DMAC7.html)
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
JP2021519267A5 (cg-RX-API-DMAC7.html)
JP2017509686A5 (cg-RX-API-DMAC7.html)
KR20090029200A (ko) 우울증 질환에 대한 치료
CN102316863B (zh) 5-苄基氨基水杨酸衍生物或其盐的医药用途
US20040229943A1 (en) Analeptic and drug combinations
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
JP4874397B2 (ja) ムスカリン性受容体m1拮抗剤を使用する精神状態の処置
JP2007513052A5 (cg-RX-API-DMAC7.html)
JP2007513052A (ja) セロトニン再取り込み阻害剤およびアゴメラチンの併用。
ES2390225T3 (es) Combinación del analéptico modafinilo y de un antidepresivo para el tratamiento de la depresión
JP2018508556A5 (cg-RX-API-DMAC7.html)
US20040242698A1 (en) Analeptic and antidepressant combinations
JP2007505156A5 (cg-RX-API-DMAC7.html)
CA2716966A1 (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
US20040229941A1 (en) Analeptic and antidepressant combinations
JP2011516604A (ja) 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の(1s,2r)鏡像異性体の使用
US20040229940A1 (en) Analeptic and antidepressant combinations
RU2021121046A (ru) Органическое соединение
CA2460348A1 (en) Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
RU2020118505A (ru) Комбинация модуляторов nmda-рецептора (рапастинеля) для применения в комбинированной терапии (расстройства сна и цнс)
Elia Side effects of antidepressants